TetraLogic Pharmaceuticals Corp. (Nasdaq: TLOG) reported disappointing results from a Phase 2 study of birinapant to treat myelodysplastic syndromes. The stock price plummeted $1.29 to $0.41.
TetraLogic reports disappointing study results
January 07, 2016 at 13:50 PM EST
